Sign In
Buy NKTX
$2.72
-0.190 (-6.53%)
At Close: Jun 03, 2026
Here's Why Nkarta, Inc. (NKTX) is Poised for a Turnaround After Losing -39.31% in 4 Weeks
10:36am, Wednesday, 28'th Jun 2023
Nkarta, Inc. (NKTX) is technically in oversold territory now, so the heavy selling pressure might have exhausted. This along with strong agreement among Wall Street analysts in raising earnings estima
Why Shares of Nkarta Are Slumping Tuesday
01:02pm, Tuesday, 27'th Jun 2023
Nkarta's lead therapy showed limited effectiveness in treating acute myeloid leukemia. Last week, there was a rash of insider selling by company executives.
Nkarta to Host Conference Call to Discuss Updated Clinical Data from NKX101 NK Cell Therapy Program
04:01pm, Monday, 26'th Jun 2023
SOUTH SAN FRANCISCO, Calif., June 26, 2023 (GLOBE NEWSWIRE) -- Nkarta, Inc. (Nasdaq: NKTX), a biopharmaceutical company developing engineered natural killer (NK) cell therapies, today announced that i
SOUTH SAN FRANCISCO, Calif., May 11, 2023 (GLOBE NEWSWIRE) -- Nkarta, Inc. (Nasdaq: NKTX), a biopharmaceutical company developing engineered natural killer (NK) cell therapies, today announced that it
7 Stocks With Promising Upside Potential for 100% Returns
12:50pm, Sunday, 07'th May 2023
While your friendly financial advisor will probably never recommend these terribly risky enterprises, sometimes, you're just in the mood for stocks with 100% upside potential. And with these ideas, yo
Nkarta to Participate at Upcoming Investor Conferences
09:06pm, Wednesday, 12'th Apr 2023
SOUTH SAN FRANCISCO, Calif., April 12, 2023 (GLOBE NEWSWIRE) -- Nkarta, Inc. (Nasdaq: NKTX), a biopharmaceutical company developing engineered natural killer (NK) cell therapies to treat cancer, today
3 Biotech Stocks to Watch for Potential Breakthroughs
09:46am, Tuesday, 11'th Apr 2023
Biotech stock fortunes hinge upon potential, progress, and the ultimate realization of drugs and devices that treat diseases. Stringent regulatory processes and long development times result in substa
Nkarta: Going Down Despite Solid Data Due To Fate's Debacle
06:37am, Sunday, 26'th Mar 2023
NKTX has consistently produced solid data from its NK cell programs. Despite that, the stock is going down.
Nkarta to Participate at Upcoming Investor Conferences
08:02am, Thursday, 09'th Feb 2023
SOUTH SAN FRANCISCO, Calif., Feb. 09, 2023 (GLOBE NEWSWIRE) -- Nkarta, Inc. (Nasdaq: NKTX), a biopharmaceutical company developing engineered natural killer (NK) cell therapies to treat cancer, today
7 Cheap But Risky Biotech Stocks
01:58pm, Wednesday, 18'th Jan 2023
Biotech stocks remain depressed, nearly two years into a dip that has seen the SPDR S&P Biotech ETF drop nearly 50%.
Nkarta to Host Conference Call to Discuss Updated Clinical Data from NKX019 NK Cell Therapy Program
04:02pm, Friday, 02'nd Dec 2022
Call scheduled for Monday, December 5, 2022 at 8:00 a.m. ET Call scheduled for Monday, December 5, 2022 at 8:00 a.m. ET
Nkarta: Under The Radar Company With Brilliant Results
12:02pm, Thursday, 10'th Nov 2022
NKTX came out with strong data in heavily pretreated AML patients in April. Data was at least as good as Fate's data, which is valued nearly 4x higher.
Nkarta to Participate at Upcoming Investor Conferences
08:02am, Wednesday, 02'nd Nov 2022
SOUTH SAN FRANCISCO, Calif., Nov. 02, 2022 (GLOBE NEWSWIRE) -- Nkarta, Inc. (Nasdaq: NKTX), a biopharmaceutical company developing engineered natural killer (NK) cell therapies to treat cancer, today
7 Unknown Biotech Stocks That Could Rocket in 2023
07:30am, Friday, 23'rd Sep 2022
Investing in early-stage or unknown biotech stocks can be likened to investing in cryptocurrency projects. If the project developments are positive, returns can be multi-folds in a short time.
Should You Buy Nkarta (NKTX) Ahead of Earnings?
09:47am, Wednesday, 10'th Aug 2022
Nkarta (NKTX) is seeing favorable earnings estimate revision activity and has a positive Zacks Earnings ESP heading into earnings season.
